Grade A (Landmark RCT) • JAMA Network Open • PMID: 35584623 • Industry Sponsored (Audited)

Urolithin A JAMA Trial: Mitophagy Activation, Muscle Endurance & hs-CRP Reduction

Official Citation: Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial (66 older adults (65-90 years old), 16 weeks) — Audited by Dr. Marcus Vance, PhD, CSCS, Exercise Physiologist & Molecular Ergogenic Researcher

Media Hype vs. Absolute Clinical Reality (Information Gain Audit)

  • Viral Headline Claim:
  • True Placebo-Adjusted Absolute Outcome: Significant improvement in muscle endurance (number of contractions until fatigue) in hand and leg muscles (+12.0% in first dorsal interosseous), alongside significant drops in plasma acylcarnitines and hs-CRP.
  • Relative vs. Absolute Statistical Breakdown: Only ~30-40% of the human population possesses the gut microbiome taxonomy (such as Gordonibacter urolithinfaciens) required to convert dietary ellagitannins into active Urolithin A, validating synthetic pure bioidentical administration.
  • Funding & Sponsor Audit: Amazentis SA (EPFL Spin-off) (Industry Sponsored (Audited))
  • Human Equivalent Dosing Protocol: 1000mg oral softgels or powder taken once daily in the morning with a meal.
Calculate Body-Weight Study Dose → Decode Target Lab Biomarker (HS-CRP) → Verify Primary PubMed Record (35584623) ↗

Related Landmark Clinical Trial Audits